Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918687 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL615494 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL2984689 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL2961846 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL5315110 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL157764 | 1.00 | NAAA (0.47) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL2980882 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL19025364 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL17433676 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL730515 | 0.98 | NAAA (0.48) | NAAARAD52NPSR1EPHX1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117982373-A | Transparent essential oil system based on white pool flower seed oil | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117982350-A | Transparent essential oil composition with squalane as main oil | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117982349-A | Transparent essential oil system based on C9-12 alkane | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117982353-A | Transparent essential oil system using liquid ester as main grease | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-117561049-A | Anti-pilling cosmetic composition | 欧莱雅 | 2024-02-13 | — | — | CN | claimed |
| CN-114306107-B | Functional skin product and preparation method thereof | 铂曼(浙江)生物科技有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-116367810-A | Cosmetic composition comprising an antimicrobial system for reducing eye irritation or discomfort | 欧莱雅 | 2023-06-30 | — | — | CN | claimed |
| CN-116113320-A | Foaming mixed alcohol/water composition containing structured oxyalkylated siloxane | 埃科莱布美国股份有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-117982373-A | Transparent essential oil system based on white pool flower seed oil | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117982350-A | Transparent essential oil composition with squalane as main oil | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117982349-A | Transparent essential oil system based on C9-12 alkane | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117982353-A | Transparent essential oil system using liquid ester as main grease | 上海家化联合股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117956984-A | Novel microparticles containing active substances | 巴斯夫欧洲公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-114795978-B | Cleansing cream | 上海佰太生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20070237746-A1 | Administration of extracts of nonfruiting nonphotosynthetic filamentous bacteria for increasing the endogenous synthesis of superoxide dismutase | SOCIETE L'OREAL S.A. (FR) | 2007-10-11 | — | — | US | disclosed |
| US-6680390-B2 | SUNSCREEN AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2004-01-20 | — | — | US | disclosed |
| US-20030082118-A1 | Use of substituted vinyltetrahydronaphthalenes and vinyl-benzotetrahydropyrans as light protection agents | PRECHTL FRANK (DE) | 2003-05-01 | — | — | US | disclosed |
| US-6524560-B1 | Light protection agents for cosmetics and pharmaceuticals which absorb predominantly in ultraviolet-A region with high absorbance, are photostable, have low intrinsic color, and are soluble in oil or water depending on substituent | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-25 | — | — | US | disclosed |
| US-20020025301-A1 | Novel flavonoids and their use in cosmetic and dermatological preparations | BASF AKTIENGESELLSCHAFT (DE) | 2002-02-28 | — | — | US | disclosed |
| US-5120711-A | Of polymyxin B and chlorquinaldol; for treatment of mastitis or fungal infections | EGIS GYOGYSZERGYAR (HU) | 1992-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025301-A1 | Novel flavonoids and their use in cosmetic and dermatological preparations | CBR1, CYP1B1, CYP1A1 | NAAA 4287/4885RAD52 154/4885NPSR1 1612/4885 |
| US-20030082118-A1 | Use of substituted vinyltetrahydronaphthalenes and vinyl-benzotetrahydropyrans as light protection agents | CBR1, CBR3, CYC1 | NAAA 4854/4885RAD52 62/4885NPSR1 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.